Cargando...
Vismodegib
Vismodegib (GDC-0449), an orally bioavailable small molecule inhibitor of Hedgehog signaling, was recently approved by the U.S. Food and Drug Administration for the treatment of basal cell carcinoma that is either metastatic or locally advanced in patients who are not candidates for surgical resecti...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2012
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3383648/ https://ncbi.nlm.nih.gov/pubmed/22653209 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrd3753 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|